Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II, or non-squamous IIIA NSCLC per American Joint Committee on Cancer (AJCC) 7th edition and have had negative margins; N3 disease is not allowed
All of the following staging criteria (according to the 7th edition of the American Joint Committee on Cancer [AJCC] Cancer Staging Manual) must be met:\r\n* By pathologic evaluation, primary tumor must be pT1-3\r\n* By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b\r\n* If pN0, pathological tumor must be >= 3.0 cm
Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition
Patients must have undergone complete surgical resection of their stage IB (>= 4 cm), II or IIIA NSCLC according to the American Joint Committee on Cancer (AJCC) 7th edition and have had negative surgical margins
Stage IV disease (includes M1a, M1b, or recurrent disease), according to the 7th edition of the lung cancer tumor, node, and metastasis (TNM) classification system
Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition staging criteria
Histologically or cytologically confirmed, resectable Stage II, IIIA, or Select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the AJCC/UICC staging system
Cytologically or histologically confirmed diagnosis of Stage IV NSCLC as defined by the American Joint Committee on Cancer Staging Criteria for Lung Cancer (AJCC 7th edition 2009).
Participants must have histologically confirmed stage IIIA or IIIB non-squamous non-small cell lung cancer (NSCLC) (American Joint Committee on Cancer [AJCC] 7th edition); patients with a clinical stage of IIIB are allowed only if they are thought to be a candidate for concurrent chemoradiation
Clinical stages T1a-T2a N0 M0 (AJCC Criteria 7th Ed.). Staging must be done by treating investigator.
Participants must have histologically confirmed stage IV non-small cell lung cancer (NSCLC) (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act [CLIA]-approved laboratory
Participants must have histologically confirmed stage IV NSCLC (per American Joint Committee on Cancer [AJCC] 7th edition) from time of diagnosis with either the L858R or exon 19 deletion activating EGFR mutation as identified in a Clinical Laboratory Improvement Act (CLIA)-approved laboratory
Patients with non-metastatic breast cancer are eligible; this includes American Joint Committee on Cancer (AJCC) 7th edition left- or right-sided breast cancer clinical or pathologic stage I, II, III or loco-regionally recurrent at time of diagnosis; for patients that receive neoadjuvant chemotherapy, AJCC 7th edition left- or right-sided breast cancer pathologic stage yp 0, I, II, III are eligible
Histologically or cytologically-confirmed recurrent or resistant (progression within 6 months following the last administered platinum based therapy or progression after subsequent therapy in previously relapsed subjects), stage III-IV epithelial ovarian, fallopian tube or peritoneal cancer subjects (according to American Joint Committee on Cancer/Union for International Cancer Control TNM and International Federation of Gynecology and Obstetrics Staging System, 7th edition) whose disease has progressed following adjuvant therapy or therapy for metastatic disease.
Has a histologically or cytologically confirmed diagnosis of stage IV (M1a or M1b-American Joint Committee on Cancer [AJCC] 7th edition) squamous NSCLC.
Pathologically proven (either histologic or cytologic) diagnosis of stage IIB-IIIB non-small cell lung cancer (NSCLC); according to American Joint Committee on Cancer (AJCC) staging, 7th edition\r\n* Staging workup must include: brain imaging (CT head or magnetic resonance imaging [MRI] brain) and PET/CT\r\n* Pleural effusions must have cytology to rule out malignant involvement unless too small to undergo thoracentesis per radiology
Patients must have stage III, IVa or IVb disease as determined by imaging studies and complete head and neck exam; staging evaluation should be in accordance with the American Joint Committee on Cancer Staging Manual, 7th edition
Histologically or cytologically proven Stage IIb-IV melanoma (at diagnosis or at the time of recurrence) rendered clinically free of disease by surgery, other therapy, or spontaneous remission within 6 months prior to registration; patients with treated brain metastases may be eligible if they meet the criteria. Small radiologic or clinical findings of an indeterminate nature will not be a basis for exclusion, and brain metastases will not be a basis for exclusion.\r\n* Staging of cutaneous melanoma will be based on the 7th edition American Joint Committee on Cancer (AJCC) staging system. Staging of mucosal melanomas will be based on the following system modified from the cutaneous melanoma staging system: 2.01- 4 mm primary with ulceration or > 4 mm primary = stage IIb, lymph node metastases = stage III, distant metastases = stage IV.
Pathologically proven (either histologic or cytologic) diagnosis of NSCLC with any of the following stages (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition):\r\n* Stage IIIA or IIIB\r\n* Stage II NSCLC with medical contraindication to curative surgical resection\r\n* Stage IV disease with solitary brain metastasis that has been treated radically (eg: with surgical resection or stereotactic radiosurgery) and thoracic disease that would be classified as stage II-III
Pathologically proven (either histologic or cytologic) diagnosis of stage IIIA or IIIB non-small cell lung cancer; (according to American Joint Committee on Cancer [AJCC] staging, 7th edition) within 4 weeks of registration; the patient should have histologically or cytologically confirmed N2 disease
AJCC (American Joint Committee on Cancer) 7th Ed. clinical stage II-III.
Must meet stage II - III group criteria per AJCC Staging manual 7th edition.
Phase I and expansion cohort: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with clinical stage: IV (see American Joint Committee on Cancer [AJCC] staging criteria, 7th edition) or stage IIB-IIIC (expansion cohort only)
Phase II: Patients must have histologically or cytologically confirmed adenocarcinoma of the breast associated with the following clinical stage: IIB, IIIA, IIIB, or IIIC (see AJCC staging criteria, 7th edition); the tumor must be human epidermal growth factor receptor 2 (Her2)/neu negative (by DAKO HercepTest, fluorescence based in situ hybridization [FISH], or other approved assay)
Pathologic stages T2-T3b, N0-Nx-N1, M0-1 as staged by the pathology report (American Joint Committee on Cancer [AJCC] criteria 8th edition [Ed.])
Patients must have a clinical T stage documented by the treating urologist/medical oncologist within 90 days prior to treatment start using the seventh (7th) edition American Joint Committee on Cancer (AJCC) staging system, recorded as the urologist’s/medical oncologist’s best clinical assessment of extent of local disease by digital rectal examination and available imaging studies such as transrectal ultrasound, computed tomography (CT) scan, and/or MRI
Subjects with histologically confirmed advanced, progressive, well-differentiated nonfunctional NET of the pancreas, lung or gastrointestinal (GI) tract per the 7th International Association for the Study of Lung Cancer classification (IASLC) or the American Joint Committee on Cancer (AJCC) staging handbook, 7th edition
Stage IV (according to the American Joint Committee on Cancer [AJCC] 8th edition).
Clinical stage T2-T4c, any N, M0 primary tumor by American Joint Committee on Cancer (AJCC) 7th edition clinical staging
Patients who have stage III-IV disease without distant metastases (M0) of 1) oral cavity, 2) larynx, 3) hypopharynx 4) oropharynx (human papillomavirus [HPV] negative [neg]) using American Joint Committee on Cancer (AJCC) 8th edition
Patients who have oropharyngeal cancer that is HPV positive, stage II-III disease without distant metastases (M0) using AJCC 8th edition
Unicentric American Joint Committee on Cancer (AJCC) 7th edition T1N0M0 tumor measuring no greater than 2.0 cm in longest dimension on initial imaging with either breast magnetic resonance imaging (MRI) and/or mammogram
Participants must have advanced disease - either stage IV disease, stage IIIB disease not amenable to definitive multi-modality therapy, or recurrent disease after a prior diagnosis of stage I-III disease; all staging is via the American Joint Committee on Cancer (AJCC)/International Association for the Study of Lung Cancer (IASLC) 7th edition proposed staging criteria
Histologically or cytologically confirmed nasopharyngeal carcinoma, stage II-IV by American Joint Committee on Cancer (AJCC) 7th edition, endemic-type (defined as World Health Organization [WHO] type 2a and 2b non-keratinizing or undifferentiated subtypes, excluding WHO type I keratinizing subtype) performed on a biopsy that occurred within 90 days of registration
Clinical stage T1-2, N0-1, or small volume N2b (American Joint Committee on Cancer [AJCC], 7th ed.), with no distant metastases, based on routine staging workup.
Clinical stage T1-T2, N1-N2b or T3, N1-N2b (American Joint Committee on Cancer [AJCC] 7th edition) with no distant metastases based on the following diagnostic workup
Suspected or histologically/cytologically confirmed oropharyngeal squamous cell carcinoma (OPSCC), stage II, III, or IVA (according to the American Joint Committee on Cancer [AJCC] 7th edition), or patients with loco-regional recurrence from an OPSCC primary, if time of recurrence is at least 6 months after completion of initial curative intent treatment (surgery or radiotherapy +/- chemotherapy or cetuximab). Patients with a suspected lesion may be enrolled and a baseline biopsy will be obtained as part of the study. If squamous cell histology is not confirmed, patients will be discontinued from the study
Clinical stage I (breast tumor >= 1.0 cm in diameter), stage II or stage III breast cancer (according to the American Joint Committee on Cancer [AJCC] Staging Manual, 7th Edition, 2010); multifocal disease is allowed if confined to 1 breast, as long as one tumor is at least 1 cm and meets all of the other inclusion criteria
Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) N2-N3 nodal disease or T3-T4 primary tumor
Patient must have pathologically-confirmed and previously untreated:\r\n* Non-small cell lung cancer, stage IIIA (T1-3 N2 M0) OR\r\n* Localized esophageal cancer, >= T2, or N+, and M0 according to the American Joint Committee on Cancer (AJCC) 7th edition staging
Stage IA-IIIA NSCLC by 8th edition American Joint Committee on Cancer (AJCC) staging (that is deemed to be surgically resectable by a board certified thoracic surgeon
Stage IIIB or IV NSCLC as per 8th edition AJCC staging
All subjects must be either recurrent or stage IV American Joint Committee on Cancer (AJCC) (7th edition) and have histologically confirmed Merkel cell carcinoma with confirmed pathology in order to be eligible
Clinical stage I-IVB (American Joint Committee on Cancer [AJCC], 7th edition); stages I-II glottic cancer are excluded
Clinical or pathologic stage Stage III-IVb per the American Joint Committee on Cancer (AJCC), 7th edition.
Stage I or II; T1N1 and T2N1 stage III presentations per AJCC 7th edition
Have pathologically confirmed diagnosis of advanced NSCLC (stage IIIB or stage IV, as defined by the American Joint Committee on Cancer staging system-TNM 7th edition, 2010)
Patients must have histologically or cytologically confirmed stage IIIB or IV (American Joint Committee on Cancer, 7th edition; AJCC 7) non-small cell lung cancer
Patient's disease state must be American Joint Committee on Cancer (AJCC) 7th edition stage I-III
Histologically or cytologically proven diagnosis of NSCLC that is locally advanced (stage IIIB) unsuitable for radiotherapy or metastatic (stage IV) according to the 7th edition of tumor, node, metastasis (TNM) in Lung Cancer published by the International Union Against Cancer and the American Joint Committee on Cancer.
Stage IIIB-IV, locally advanced or metastatic disease according to the 7 th edition of the AJCC lung cancer TNM classification system
Patients must have FDG-avid and pathologically proven Stage IIA-IIIB non-small cell lung cancer (NSCLC) (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
Clinical stage =< T2b (American Joint Committee on Cancer [AJCC] 7th Edition Staging Manual) and no radiographic evidence of T3 or T4 disease
Clinical American Joint Committee on Cancer (AJCC) 7th edition stage T2N1M0, T3N0M0 or T3N1M0 based on physical examination, CT scan chest/abdomen/pelvis, and pelvic magnetic resonance imaging (MRI) or endorectal ultrasound
Documented history of clinical stage IV (any T, any N, M1a/b) disease as per American Joint Committee on Cancer (AJCC) staging system 7th edition
Patients must be classified post-operatively as Stage IB (? 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).
Clinical American Joint Committee on Cancer (AJCC) stage (7th edition) IIA-IIIB NSCLC (T1-4N0-3M0)
Patients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIIC
Clinical stage a =< T1-2a (American Joint Committee on Cancer [AJCC] 7th edition)
Pathologically proven (either histologic or cytologic) diagnosis of stage IV or recurrent non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
Clinical stage T1-2b (American Joint Committee on Cancer [AJCC] 7th edition) and PSA < 20 ng/mL within 90 days prior to registration; PSA should not be obtained within 10 days after prostate biopsy
Histologically confirmed stage III colorectal cancer as determined by American Joint Committee on Cancer (AJCC) 7th edition
Patients must have documented, clinically measurable 7th edition American Joint Committee on Cancer (AJCC) stage IIIB/C (bulky nodal and/or in transit disease) or stage IV (distant metastatic) melanoma; patients with brain metastases that have been appropriately treated with surgical resection and/or radiation are eligible for inclusion if they meet the performance status and life expectancy criteria; patients who are BRAF V600E mutation positive need to have failed, refused, or be ineligible for at least 2 lines of therapy (vemurafenib plus one other regimen)
Clinical stage T1b-T2b, N0-Nx, M0-Mx (American Joint Committee on Cancer [AJCC] 6th Edition)\r\n* T-stage and N-stage determined by physical exam and available imaging studies (ultrasound, computed tomography [CT], and/or magnetic resonance imaging [MRI])\r\n* M-stage determined by physical exam, CT or MRI; bone scan not required unless clinical findings suggest possible osseous metastases
Patients must have a histologically or cytologically confirmed, unresectable, advanced or metastatic (Stage IV per AJCC 7th edition TNM staging) NSCLC
Patient with histologically or cytologically confirmed non-resectable or metastatic stage 3 (non-resectable IIIB or IIIC, AJCC TNM staging system 7th edition) or stage 4 melanoma
Clinical stage II or stage III (by American Joint Committee on Cancer [AJCC] 7th edition) breast cancer eligible for neoadjuvant chemotherapy with complete surgical excision of the breast cancer after neoadjuvant therapy as the treatment goal
Stage IV disease or stage IIIC disease (using the 7th edition American Joint Committee on Cancer [AJCC] criteria) not amenable to local therapy
If both of the following conditions are present, the patient is ineligible:\r\n* < 10 pack-year smoking history\r\n* p16-positive carcinoma of the oropharynx or unknown primary that are T0-3, N0-2b (AJCC 7th Edition)\r\n** Note: in the event that a registered patient has a p16-positive result on central review with the tumor and nodal stage T0-3, N0-2b (AJCC 7th Edition), then the site will be notified that the patient is ineligible
Participants must have presented at initial diagnosis with extensive-stage disease (defined as stage IV [T any, N any, M1a/b] per National Comprehensive Cancer Network [NCCN] guidelines version 1.2015, American Joint committee on Cancer [AJCC] staging manual, seventh [7th] edition, 2010)
Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC); patients should have stage IV disease (American Joint Committee on Cancer [AJCC] 7th edition), stage IIIb disease that is not amenable to potentially curative treatment (e.g. chemoradiotherapy) or unequivocal progression in a prior irradiated field; measurable or evaluable disease is required
Oropharyngeal primaries have to be human papillomavirus (HPV) p16 negative, unless by American Joint Committee on Cancer (AJCC) 7th edition staging they are cT4a, cT4b, cN2 and/or cN3 tumors
Patients with stage IV (locally advanced or metastatic) disease; the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th edition will be used for staging; Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria will be used for measurable disease
Patients must have histologically or cytologically confirmed:\r\n* Extensive stage small cell lung cancer (SCLC) or \r\n* Stage IV (M1a or M1b according to American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition) large cell neuroendocrine non-small cell lung cancer (NSCLC) or \r\n* Small cell carcinoma of unknown primary or extrapulmonary origin and must be a candidate for systemic therapy \r\n** NOTE: The extensive disease SCLC classification for this protocol includes all patients with disease sites not defined as limited stage; limited stage disease category includes patients with disease restricted to one hemithorax with regional lymph node metastases, including hilar, ipsilateral and contralateral mediastinal, and/or ipsilateral supraclavicular nodes; extensive disease patients are defined as those patients with extrathoracic metastatic disease, malignant pleural effusion, bilateral or contralateral supraclavicular adenopathy
Patient must have histologically or cytologically confirmed oral cavity squamous cell carcinoma of stage 2, 3, 4a, or 4b (by American Joint Committee on Cancer [AJCC] 7th edition [ed.])
Patients must be clinical American Joint Committee on Cancer (AJCC) stage IIIA or IIIB (AJCC, 7th ed.) with non-operable disease; non-operable disease will be determined by a multi-disciplinary treatment team, involving evaluation by at least 1 thoracic surgeon within 8 weeks prior to registration; Note: For patients who are clearly nonresectable, the case can be determined by the treating radiation oncologist and a medical oncologist, or pulmonologist
Pathologically proven diagnosis of stage IIIA (T1-T3) (American Joint Committee on Cancer [AJCC] Staging, 7th edition) with a single primary lung parenchymal lesion and ipsilateral positive mediastinal nodes within 12 weeks of registration; note: the primary tumor does not require tissue diagnosis; documentation of non-small cell carcinoma may originate from the mediastinal node biopsy or aspiration
Patients must have histologically or cytologically confirmed stage IV (American Joint Committee on Cancer [AJCC] 7th Edition) or recurrent non-small cell lung cancer (NSCLC)
Complete surgical resection, pathologic stage IA-B, IIA-B, IIIA-B by the American Joint Committee on Cancer (AJCC) 7th Edition staging criteria
Patients with synchronous disease at initial diagnosis must have metastatic (M1) disease (American Joint Committee on Cancer [AJCC] 7th edition T1-4N0-1M1)
Patients must have appropriate staging studies identifying them as American Joint Committee on Cancer (AJCC) stage II or III non small cell lung cancer, (according to AJCC staging, 6th edition), or recurrent non small cell lung cancer; histologic confirmation of cancer will be required by biopsy or cytology within 9 months of study entry
Stage IV locally advanced or metastatic urothelial carcinoma (according to American Joint Committee on Cancer 7th edition guidelines) with documented disease progression while on a PD-1 pathway targeted therapy.
Patients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligible
Pathologically or cytologically confirmed NSCLC Stage IV Cancer (includes cytologically proven pleural effusion or pericardial effusion) or recurrent disease. Staging is based on American Joint Committee on Cancer (AJCC) Staging for NSCLC 7th edition (R12-4710)
Histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) Staging Manual (8th edition)
Pathologically (histologically or cytologically) proven diagnosis of NSCLC with unresectable, medically inoperable disease, or patients who refuse resection stage IIIA or stage IIIB disease (AJCC 7th edition)
There must be histologic confirmation of high risk, adenocarcinoma of the colon defined as AJCC 7th Edition Stage IIIB or IIIC.
Pathologically confirmed (histology or cytology) clinical Stage II, III, or IVA squamous cell cancer of the oral cavity (excluding lip). Subjects must be staged using AJCC Cancer Staging Manual Edition 7.0 (appendices 1 and 2).
Stage IIIC colorectal cancer (T4a, N2a, M0) or (T3-4a, N2b, M0), or (T4b, N1- N2, M0) (per AJCC 7th ed).
Have stage IV disease at the time of study entry (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition).
Stage IB (with a primary tumor >= 4cm), IIA, IIB, or IIIA (according to American Joint Committee on Cancer [AJCC] 7th edition); patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor
Participant has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior systemic platinum based chemotherapy.
Stage II or III esophageal carcinoma according to the American Joint Committee on Cancer (AJCC) 7th edition staging
Patients with American Joint Committee on Cancer (AJCC) (7th edition, 2010) T1-T4 nodal stage N2 or N3 or a T3 or T4 primary tumor with any nodal stage
Clinical American Joint Committee on Cancer (AJCC) stage II-III (AJCC, 7th ed.) with plans to be treated with concurrent chemoradiotherapy\r\n* Recurrent non-small cell lung cancer is allowed, provided the intent of the current treatment is curative and there has been no prior radiation to the thorax\r\n* Prior chemotherapy, immunotherapy, or targeted therapy is permitted as long as patients have recovered from prior toxicities to grade =< 1
American Joint Committee on Cancer (AJCC) (7th edition) stage IIb, III, or IV patients planned for resection of the primary tumor \r\n* > 5 cm in greatest dimension\r\n* Intermediate or high-grade \r\n* Superficial or deep
COHORT A: History or presence of regional pelvic lymph nodes (as per American Joint Committee on Cancer [AJCC] Cancer Staging [7th edition]) will be considered a metastatic site if greater than 1.5 cm in shortest dimension
Any clinical T4 tumor as defined by tumor-node-metastasis classification in UICC/AJCC 7th edition, including inflammatory breast cancer
Clinical stage T1-2, N1-2c (American Joint Committee on Cancer [AJCC], seventh [7th] edition [ed.]) without evidence of distant metastasis based on fludeoxyglucose (FDG) PET/CT\r\n* Patients who have squamous cell carcinoma of the neck of unknown primary, and thus, are T0, are allowed with excision biopsy of a lymph node (or core biopsy) and consent from the principal investigator (PI) or coorperative (co)-PIs (Dr. Nancy Lee, Dr. Eric Sherman, or Dr. Nadeem Riaz)
With histologically or cytologically confirmed recurrent or refractory unresectable Stage IV gastric or gastro-esophageal junctional adenocarcinoma (according to American Joint Committee on Cancer/Union Internationale Contre le Cancer [UICC] 7th edition) and whose disease progressed after one or two prior chemotherapy regimen(s) involving both fluoropyrimidines and platinum
PART A: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the American Joint Committee on Cancer [AJCC] staging manual)
PART B: Patients must have histologically confirmed locally advanced (after failure of local therapy) or metastatic lung cancer (any histology, except carcinoid) stage IIIa, IIIb or IV (according to the 7th edition of the AJCC staging manual)
Suspected or histologically/cytologically confirmed head and neck squamous cell carcinoma (HNSCC) of the oral cavity, stage III, IVA or IVB (according to the American Joint Committee on Cancer [AJCC] 7th edition); patients with a suspected lesion may be enrolled and a baseline biopsy will be obtained as part of the study; if squamous cell histology is not confirmed, patients will be discontinued from the study
Stage IV disease by AJCC criteria (7th edition).
Stage II or III disease by the American Joint Committee on Cancer (AJCC) 7th edition
STEP 1 ENROLLMENT: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th Edition stage IV NSCLC
STEP 2 ENROLLMENT AND RANDOMIZATION: the patient has a diagnosis of American Joint Committee on Cancer (AJCC) 7th edition stage IV NSCLC
Biopsy-proven invasive adenocarcinoma of the rectum, stage T3-4 and/or node-positive (American Joint Committee on Cancer [AJCC] stage II or III) per AJCC staging manual, 7th edition; patients with M1a rectal cancer (“metastasis confined to one organ or site [e.g., liver, lung, ovary, non regional node]\), stage IVA disease per the AJCC staging manual, 7th edition, are also eligible; for the purpose of this study, a tumor is located in the “rectum” when its distal edge is located =< 12cm from the anal verge; the distal edge of the tumor can be delineated by digital examination or endoscopic examination, including colonoscopy, although rigid proctoscopy is preferred
Histological diagnosis:\r\n* Histologically proven diagnosis of testicular seminoma\r\n** Histologically confirmed seminomatous germ cell tumor of the testis categorized as either \classical\ or \anaplastic”\r\n* Stage I disease\r\n** Any pT N0 M0 S0-3 (American Joint Committee on Cancer [AJCC], 7th Ed.)\r\n* Stage IIA or IIB disease\r\n** Any pT N1 M0 S0-3 (AJCC, 7th Ed.)\r\n** Any pT N2 M0 S0-3 (AJCC, 7th Ed.)\r\n** (At the discretion of the principal investigators, bulky stage IIB may be excluded from the study, according to National Comprehensive Cancer Center Guidelines)
Stage IV disease according to the 7th Edition of the American Joint Committee on Cancer staging system
Histologically or cytologically confirmed soft-tissue sarcoma, excluding alveolar and embryonal rhabdomyosarcoma, well- and dedifferentiated adipocytic sarcomas, Ewing’s, osteosarcoma, or gastrointestinal stromal tumor; American Joint Committee on Cancer (AJCC) (6th Edition) Stage III or T2a Stage II or Stage IV treatment naive patients planned for resection of the primary tumor, with resectable metastatic disease
Patients with American Joint Committee on Cancer (6th edition, 2002) stage IV cancer with distant metastases
The patient must have clinical stage T1-4, N0-3, M0-1, stage II-IVC carcinoma as per the 7th edition of the American Joint Committee on Cancer (AJCC) staging manual; patients with T1N0M0 will be ineligible; patients with metastatic disease with a limited metastatic burden are eligible if obtaining local control is determined by their treating oncologist to be an important therapeutic goal
Patients with FDG-avid and pathologically proven stage IIA-IIB or IIIA-IIIB non-small cell lung cancer (according to American Joint Committee on Cancer [AJCC] staging, 7th edition)
For Phase II: Histological diagnosis of BRAF V600E/K melanoma, unresectable stage III or stage IV, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2011; must have measurable disease, and no prior systemic treatment for locally advanced or metastatic melanoma; previous local therapy is allowed; previous systemic treatment for any stage III disease that was subsequently rendered NED (no evidence of disease) by surgery is allowed except for ipilimumab and BRAF inhibitors; patients with resectable disease who do not want surgery for any reason are also allowed; measurable disease is defined as least one lesion that can be accurately measured in two dimensions with both diameters >= 1.0 cm; for computed tomography (CT)/magnetic resonance imaging (MRI) evaluations, an effective slice thickness is required of less than or equal to 5 mm; for slice thickness greater than 5 mm, both diameters must be greater than or equal to 2.0 cm at baseline
Patients with cytologically or histologically confirmed non-small cell lung cancer (NSCLC) – locally advanced, stage IIIB OR stage IV or stage IVM1A (malignant pleural or pericardial effusion or pleural implants) OR recurrence after primary surgery or radiotherapy (refer to 2010 American Joint Committee on Cancer [AJCC] staging, 7th edition [Ed])
Histologically-confirmed NSCLC Stage IV disease (according to the seventh edition of the lung cancer staging system)
Resected, histologically proven, cutaneous melanoma determined to be Stage IIb, IIc, or III; according to the American Joint Commission of Cancer Staging, 7th edition
All patients must be either Stage IIIb/c or Stage IV according to the American Joint Committee on Cancer (AJCC) (7th edition) and have histologically-confirmed melanoma that is felt to be surgically unresectable in order to be eligible. Please refer to the AJCC Cancer Staging Manual, 7th edition for a description of tumor, lymph node, metastasis and staging.
Subjects with a confirmed or suspected diagnosis of stage IA to stage IIIA non-small cell lung cancer scheduled for a lobectomy (Lung Cancer Staging per American Joint Committee on Cancer,7th Edition)5;
Histologically or cytologically confirmed and documented stage IIIb/IV non-squamous NSCLC according to the American Joint Committee on Cancer Staging Manual (7th Edition)
Histologically or cytologically proven adenocarcinoma of the breast stages II-III, according to the American Joint Committee on Cancer (AJCC) Staging Manual, 7th Edition, 2009
Patient who have AJCC 8th edition Prognostic Stage Group II
Patients must have histologically or cytologically confirmed stage I-III breast cancer (as defined by the revised, American Joint Committee on Cancer [AJCC] 7th edition criteria) and be at sufficient risk for tumor recurrence; staging studies to exclude metastatic disease are not required in asymptomatic patients; however, patients with findings considered suspicious for metastatic disease on any staging studies that are obtained need to be evaluated to exclude stage IV breast cancer
Diagnosis of RCC that is defined as metastatic by standard criteria (American Joint Committee on Cancer [AJCC] 7th edition, 2010)
Enrolled in 7th or 8th grade
Histologically confirmed stage IV gastrointestinal (GI) cancer (American Joint Committee on Cancer [AJCC] 7th edition) currently sensitive to oxaliplatin containing chemotherapy regimen
Patients with American Joint Committee on Cancer (AJCC) 7th edition clinical stage IIB-IIIC
Patient must have proven or suspected non small cell lung cancer (NSCLC) and be clinical stage I or IIa, according to the 7th edition staging system of the American Joint Commission on Cancer for lung cancer (T1 or T2a, N0 or N1, M0)
Stage T1-4bN1-2, by the American Joint Committee on Cancer (AJCC) 7th edition, based on the following minimum workup:\r\n* CT chest/abdomen with contrast\r\n* MRI pelvis with contrast\r\n* PET/CT of the whole-body or skull base to mid-thigh
Subjects with AJCC 7th edition stage TxN0 and M1 disease
Subjects with AJCC 7th edition stage TxN0, T4b, and M1 disease
Patients must have pathologically confirmed diagnosis of unilateral ductal carcinoma in situ with no evidence of microinvasive or invasive disease obtained by core needle biopsy within 4 months of registration; if the core biopsy describes “suspicion of microinvasion”, patients remain eligible; patients diagnosed by surgical excision are not eligible; patients with synchronous bilateral disease (i.e.,\r\nsynchronous DCIS or invasive cancer) are not eligible\r\n* Patients will be staged prior to registration according to the clinical staging criteria adapted from the American Joint Committee on Cancer (AJCC) Cancer Staging Data Forms of the AJCC Cancer Staging Manual, 7th Edition, 2009; Note: for consistency purposes, AJCC 7th Edition will continue to be used throughout the entire study enrollment period
Patients must have stage I or II disease based on the parameters for staging NSCLC found in the American Joint Committee on Cancer (AJCC) cancer staging handbook, seventh (7th) edition
Patient must have stage IIIA non-small cell lung cancer (T1-3N2) per American Joint Committee on Cancer (AJCC) 7th edition and must be considered to be surgically resectable
Eligible patients must have appropriate staging studies identifying them as specific subsets of American Joint Committee on Cancer (AJCC) 7th edition stage I or II based on only one of the following combinations of tumor, nodes, metastatic (TNM) staging:\r\n* T1a-b, N0, M0\r\n* T2a, N0, M0\r\n* T3 (invading the chest wall, < 5 cm in diameter) N0 M0
Patient must have clinical American Joint Committee on Cancer, 6th edition stage II or III breast cancer and be considered a candidate for curative mastectomy
American Joint Committee on Cancer (AJCC) 7th edition (ed.) stage cN0 or cN1 subsequently staged after surgery as stage pIB (N1mic), pIIA, pIIB, pIIIA, pIIIB, or N3a (10 or more axillary nodes) only: note that ypN0 will also be eligible if pathologic confirmation of nodal involvement was documented prior to neoadjuvant chemotherapy and the patient was found to be node negative at the time of surgery; note that women less than 50 years of age, women who received chemotherapy, patients staged as pN0 (i+ or mol+), and large-breasted women are eligible for enrollment
